Latest Breaking News On - Ivor macleod - Page 1 : comparemela.com

SCYNEXIS : 10-K Filing | MarketScreener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K . | March 31, 2023

State of new jerseyNew jerseyUnited statesHong kongUnited kingdomNew south walesSouth africaRussian federationDavid hastingsBrian philippe tinmouthMarco tagliettiAzoles noxafilStevenc gilmanChristine coyneHistoplasmaandblastomycesgenera candidaandaspergillusgeneraArmando anido

SCYNEXIS, Inc (SCYX) Q3 2022 Earnings Call Transcript

SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.

United statesLouise chenDebbie etchisonMarco tagliettiShubhendu sen royMichael higginsDavid anguloIvor macleodExchange commissionCompany participantsLadenburg thalmannWorld health organizationScynexis incConference call novemberSen royExecutive director

Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer

25.10.2022 - Brings deep industry experience spanning financial and operational roles to support Company and its new strategic directionJERSEY CITY, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering . Seite 1

United statesMarco tagliettiIvor macleodEisai co ltdGlobe newswire scynexis incRoche incMerck research labs at co incEisai incAthersys incChief financialChief executive officerChief financial officerChief compliance officerVice president financeResearch labsNorth american chief financial officer

Scynexis (SCYX) Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

Scynexis (SCYX) Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Christine coyneMarco tagliettiDavid anguloIvor macleodAmplity healthScynexis incAthersys incWall streetChief executive officerChief medical officerChief financial officerChief commercial officer

SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

20.10.2022 - SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date . Seite 1

Christine coyneMarco tagliettiDavid anguloIvor macleodGlobe newswire scynexis incAmplity healthChief executive officerChief medical officerChief financial officerChief commercial officer